Previous 10 | Next 10 |
BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2021 Earnings Conference Call Nov 02, 2021 08:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & Chief Executive Officer Linda Shapiro - Chief Medical Officer ...
Rhythm Pharmaceuticals (NASDAQ:RYTM): Q3 GAAP EPS of -$0.70 beats by $0.10. Revenue of $1.02M beats by $0.12M. Press Release For further details see: Rhythm Pharmaceuticals EPS beats by $0.10, beats on revenue
-- U.S. and EU regulatory filings submitted for IMCIVREE ® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway -- -- Delivered a total of 22 presentations at three major medical conferences -- -- New presentat...
-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS -- -- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2 Basket Trial and new data on utilization of URO ® genetic testing program –...
Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$0.80 (-3.9% Y/Y) and the consensus Revenue Estimate is $0.9M. Over the last 3 months, EPS estimates have seen 1 upward revision and 3...
OTCQX:ACDVF,AHH,AME,APO,OTCQX:ARBKF,ARCB,ARNC,AROC,AVNS,BCC,BHC,BLD,BLMN,BP,CEIX,CEN,CMI,COP,CRSR,CTLT,DD,DEA,EL,EOLS,EPD,ESPR,ETN,ETRN,EXTR,FMS,OTCPK:FSNUF,GLDD,GLYC,GNRC,GPN,HEP,HSIC,IAA,IART,IDXX,IEP,INCY,INGR,IPGP,IT,KKR,KOPN,LCII,LDOS,LEA,LGIH,LPX,MGY,MIME,MLM,MMP,MPC,MPLX,MYGN,OTCQB:NLS...
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast...
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has submitted its Type II variation applicat...
-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results from Uncovering Rare Obesity ® testing program suggest up to 64.5 pe...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...